

Oral Presentations:

DATE / TIME	STUDY	TITLE / SPEAKER	LOCATION
Thurs, 08 Oct. 11:00 - 12:30		The choice of indicators influences who is identified as priority populations for HIV epidemic response: a combined analysis of 15 mathematical models from 10 African countries - Romain Silhol	Limatambo 3 /Channel 1
Tues, 08 Oct. 15:30 - 17:00	HVTN 127/ HPTN 087, HVTN 130/ HPTN 089, HVTN 136/ HPTN 092	Pharmacokinetic interaction assessment of the HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 HIV prevention trials HVTN127/HPTN087, HVTN130/HPTN089 and HVTN136/HPTN092 - Tariro Dianah Chawana	Limatambo 5 /Channel 3
Tues, 08 Oct. 15:30 - 17:00	HVTN 804/ HPTN 095	Analytical treatment interruption (ATI) in Peru among MSM, trans & gender non-conforming (GNC) individuals with early ART initiation +/- VRC01 proximate to HIV acquisition: Stakeholder engagement & early clinical data - Jorge Gallardo-Cartagena	Limatambo 5 /Channel 3
Tues, 08 Oct. 15:30 - 17:00	HVTN 140/ HPTN 101	Phase 1 dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics and neutralization activity of PGDM1400LS in combination with VRC07-523LS and PGT121.414.LS in healthy participants without HIV (HVTN 140/HPTN 101) - Sharana Mahomed	Limatambo 5 /Channel 3
Wed, 09 Oct. 11:00 - 12:30	HVTN 127/ HPTN 087, HVTN 130/ HPTN 089, HVTN 136/ HPTN 092, HVTN 140/ HPTN 101	Assessment of infusion-related reactions after intravenous administration of HIV monoclonal antibodies PGT121.414.LS, PGDM1400.LS or VRC07-523LS (alone or in combination with PGT121, PGDM1400, 10-1074, PGT121.414.LS, PGDM1400.LS), in five phase 1 studies - Silvia P Goulart	Cusco Ballroom /Channel 4
Thurs, 10 Oct. 13:00 - 14:30	HPTN 084	Evaluation of potential pharmacologic interactions between CAB-LA or TDF/FTC and hormonal contraceptive agents: a tertiary analysis of HPTN 084 - Mark Marzinke	Limatambo 3 /Channel 1
Thurs, 10 Oct. 08:30 - 10:00	HPTN 091	PrEP uptake and adherence among transgender women: findings from a randomized clinical trial of a multicomponent intervention (HPTN 091) - Tonia Poteat	Limatambo 2 /Channel 2

Posters:

STUDY	TITLE / PRESENTER
HPTN 083-01	"I am definitely smart enough to make this decision and I know what I'm doing": self-efficacy and HIV prevention education in the first US adolescent, CAB-LA PrEP study- HPTN 083-01 - Makhosazane Nomhle Ndimande-Khoza
HPTN 084	Exploring relationship dynamics: the impact of disclosure and partner influence on oral and injectable PrEP adherence among users and their intimate partners - HPTN 084 qualitative findings - Amber Babinec
HPTN 091	Engaging community stakeholders in preparation for HPTN 091, a study integrating HIV prevention, gender-affirming medical care, and peer health navigation to prevent HIV among transgender women in the Americas - Jonathan Lucas
HVTN 805/ HPTN 093	HVTN 805/HPTN 093/A5393 Analytical Treatment Interruption (ATI) among African women with early ART initiation +/- VRC01 received within 8 weeks of HIV acquisition: safety, viral rebound and virologic control - Shelly Karuna
HPTN 111	Engagement and training of barbers to deliver an HIV prevention intervention to their clients - HPTN 111 - Joel Maena
HVTN 130/ HPTN 089, HVTN 136/ HPTN 092, HVTN 140/ HPTN 101	Acceptability of intravenous (IV) and subcutaneous (SC) infusion administration of monoclonal antibody (mAb) combinations: VRC07-523LS with PGT121, PGDM1400, PGT121.414.LS and PGDM1400LS in phase 1 anti-HIV mAb trials - Maija Alanya Anderson

E-Posters:

HVTN 805/ HPTN 093	Facilitators, barriers and robust informed consent for HVTN805/HPTN093/A5393 analytical treatment interruption (ATI) participation: insights from ATI participants and decliners screened from the antibody mediated prevention (AMP) study in Southern Africa - Shelly Karuna
HPTN 108	Recommendations made during Ccommunity consultations for analytical treatment interruption (ATI) HIV research studies in Southern Africa - Matshidiso Adelaide Malefo